Interdigital Technology Corporation & Ors. v. Guangdong Oppo Mobile Telecommunications Corp. Ltd. & Ors.

196305516

The application sought clarification on the extent to which Interdigital's Patent Licensing Agreements (PLAs) should be disclosed to the in-house employees of Guangdong Oppo Mobile, who are part of a Confidentiality Club. The court ruled that both parties must follow a reciprocal disclosure model, requiring full access to PLAs for all members of the Confidentiality Club.

Jurisdiction
India
Court
Delhi High Court
Case Number
196305516
Decision Date
19 September 2024

Detailed Summary

When billion-dollar patent battles unfold across multiple jurisdictions, the question of who gets to see what can become just as important as the patents themselves. In the high-stakes world of standard-essential patents and FRAND negotiations, confidentiality is both a shield and a weapon. But what happens when one side wants to limit who within the opposing team can view sensitive licensing agreements? A recent ruling between two major technology players offers a sharp reminder: in the courtroom, the principle of parity is non-negotiable.

Interdigital Technology Corporation, a well-known patent holder in wireless and video coding technologies, found itself in parallel proceedings against Guangdong Oppo Mobile, one of the world's largest smartphone manufacturers. These proceedings involved confidential information, particularly Interdigital's Patent Licensing Agreements (PLAs). To manage the flow of sensitive commercial data, the parties had established a Confidentiality Club, a restricted group of authorized individuals permitted to access designated confidential materials. The dispute arose when clarification was sought on a critical procedural question: should Interdigital's PLAs be disclosed to all in-house employees of Oppo who were members of this Confidentiality Club, or could access be narrowed further? This seemingly narrow procedural issue carried enormous strategic weight, because PLAs often reveal pricing terms, royalty structures, and competitive intelligence that could shape parallel FRAND (Fair, Reasonable, and Non-Discriminatory) negotiations.

Interdigital argued that the principle of parity demanded full and reciprocal disclosure. If Oppo's in-house employees within the Confidentiality Club were entitled to view Oppo's own sensitive agreements, then Interdigital's PLAs had to be made equally available to all members of that same club. Oppo, on the other hand, appeared to push for a narrower scope of disclosure, seeking to restrict which of its in-house personnel could access the competitor's licensing terms. The legal friction centered on a fundamental question of fairness: in a regime designed to balance confidentiality with the adversarial process, can one party cherry-pick who on the opposing side gets to see the evidence? The court was asked to draw the line between legitimate confidentiality protections and procedural gamesmanship.

The court ruled decisively in Interdigital's favor, establishing that both parties must operate under a reciprocal disclosure model. Under this framework, full access to the Patent Licensing Agreements must be granted to all members of the Confidentiality Club, regardless of which side they belong to. The court reinforced that the principle of parity governs confidential disclosure in such proceedings. Neither party could restrict access in a way that created an informational asymmetry within the authorized group. The ruling ensured that Oppo's in-house employees who were part of the Confidentiality Club would have the same comprehensive access to Interdigital's PLAs as Interdigital's representatives had to Oppo's confidential materials. This outcome preserved the integrity of the parallel proceedings and ensured that the FRAND negotiations and litigation could proceed on a level playing field.

For founders, startup leaders, and IP professionals navigating complex litigation involving confidential information, the lesson is clear: courts will not tolerate one-sided disclosure regimes. If you establish a Confidentiality Club, expect it to function as a two-way street. Any attempt to limit which members of the opposing party can view sensitive agreements will likely be rejected in favor of mutual, comprehensive access. When entering parallel proceedings such as FRAND negotiations alongside litigation, build your strategy on the assumption that parity will be enforced. Design your confidentiality protocols from day one with reciprocity in mind, and never assume that procedural maneuvering can shield your most sensitive commercial terms from the eyes of your adversary's authorized representatives.

Practitioner Note

This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court. Understanding the court's reasoning in Interdigital Technology Corporation & Ors. vs Guangdong Oppo Mobile Telecommunications Corp. Ltd. & Ors. is valuable context for structuring arguments or assessing risk in similar proceedings.

Related Cases

patent125259366

Merck Sharp & Dohme Corp.vsAngels Pharma India Private Limited

Merck Sharp & Dohme Corp. filed a suit alleging that Angels Pharma India Private Limited was attempting to manufacture and infringe its Indian Patent No. 209816, which covers the drug SITAGLIPTIN. The court found that the plaintiffs had established a prima facie case and granted interim relief.

patent87970164

Alfa Laval Corporate AbvsClean Earth Energy Solution India Private Limited & Anr.

The Plaintiff filed an application seeking directions for the inspection of heat exchanger plates manufactured by the Defendant and taking on record relevant documents. The Court, relying on Section 115(1) of The Patents Act, appointed a Scientific Advisor to conduct an inspection and provide a detailed report comparing the impugned products with Patent No. 322307.

patent176800166

Master Arnesh ShawvsUnion Of India & Anr.

The petition addressed the extremely cumbersome and long-drawn process for procuring rare disease medicines on a patient-by-patient basis. The court directed M/s. Sarepta Therapeutics to place on record a general bulk procurement process and provide details of all its granted patents and patent applications filed in India concerning DMD patients.

patent127816668

M/s.Guangzhou Ocusun Ophthalmic Biotechnology Company LimitedvsJoint Controller of Patents & Designs

The appeal challenged the rejection of Patent Application No. 202147005676 for a crystal form of lanosterol prodrug compound. The appellant argued that the invention exhibited significant therapeutic efficacy, particularly in reducing cataract symptoms in neonatal rabbits. The High Court found that the impugned order failed to properly consider the experimental data demonstrating pharmacodynamic studies and set aside the rejection, remanding the matter for reconsideration.

patent152799964

Malpani EnterprisesvsRegistrar Of Trade Marks

The Delhi High Court ruled in favor of Malpani Enterprises, directing the Registrar of Trade Marks to accept and proceed with its Notice of Opposition. The core issue was a technical glitch in the online filing portal which prevented the petitioner from meeting the deadline. Given that the respondent admitted the statutory period had not lapsed, the court held that a party should not suffer due to administrative or technical failures, thereby setting aside the rejection letter.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call